P2RY12 and atrial fibrillation: In the ENTRUST-AF PCI (Evaluation of the Safety and Efficacy of anEdoxaban-Based Compared to a Vitamin K Antagonist-Based Antithrombotic Regimen inSubjects With Atrial Fibrillation Following Successful Percutaneous CoronaryIntervention With Stent Placement) trial, AF patients who underwent PCI wererandomly assigned to edoxaban (60 mg once daily) plus P2Y12 inhibitor or VKAplus DAPT.